Neuroscience

Sitting Down With… Danny Bar-Zohar, Global Head of Neuroscience Development at Novartis, Switzerland.

Could activated T cells play a major role in driving neurodegeneration in glaucoma?

For better diagnosis and monitoring of Alzheimer’s disease, as well as drug R&D, we need to move toward widespread use of MRI biomarker imaging.

A simple yet accurate model could help streamline ROP screening

Introducing the easy-to-use system that offers patients lower risks of complications – regardless of surgeon experience

Researchers identified the cell types associated with schizophrenia mutations

With big pharma seemingly pulling out of the field, what hope remains for novel treatments for Alzheimer’s disease?

Could artificial intelligence help repurpose old drugs for suffers of the degenerative disorder?

What if, instead of waiting for a donor cornea to become available, you could just print one?

The promise of genome editing is tempered for genetically heterogeneous diseases – introducing a new approach for rhodopsin-dependent retinitis pigmentosa.